Madrigal Pharma (MDGL) Misses Q4 EPS by 44c

Madrigal Pharma (NASDAQ: MDGL) reported Q4 EPS of ($5.68), $0.44 worse than the analyst estimate of ($5.24).

For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00
• Medtronic completes $550 million Scientia Vascular acquisition